In conclusion, systemic levels of MCP-4 could prove an excellent asthma biomarker that can predict susceptibility to asthma, the severity of asthma exacerbations, and therefore potentially the efficacy of asthma control medicines. The gene discussed is CCL13; the disease is asthma.